Enzo Biochem (ENZ) Unit Updates on Sulfated Tyrosine

July 6, 2011 8:39 AM EDT
Enzo Biochem Inc. (NYSE: ENZ) reports scientists from its Enzo Therapeutics group presented a podium session entitled “The Presence of Sulfated Tyrosine In Scelerostin and Dkk1 Ligands and its Effect on Wnt Signaling” at the WNT 2011 conference in Los Angeles Thursday, June 30, 2011.

The work performed by Enzo’s scientific team showed the existence of an entirely new class of modification of scelerostin and Dkk proteins which exhibit significant biological function. These proteins have been shown to inhibit the Wnt signaling pathway, and therefore mediate the development of numerous diseases. As an example, fluctuation in the level of these proteins has been shown to affect such serious conditions as osteoporosis. It has been reported that anti-scelerostin anabolics are among the most exciting development in the treatment of bone disorders.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA